UNSPSC 51172437: Betaine/protease

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172437 Betaine/protease, a Commodity code, encompasses enzymatic additives and biochemical reagents for drug testing, clinical diagnostics, and pharmaceutical applications that state and local governments procure as components of specimen processing, laboratory confirmation protocols, and therapeutic drug-monitoring programs. Recent opportunities show state and local bodies purchasing these materials as part of integrated drug-testing services, laboratory supply contracts, and pharmaceutical benefit program implementations rather than as standalone chemical commodities.

State and local issuing bodies under this code include county corrections departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state and multi-jurisdiction pharmacy networks. Collin County Community Supervision and Corrections Department in Texas posted RFP 2026-327 on July 9, 2026, requesting offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026; the scope includes immunoassay screening with LC/MS/MS or GC/MS confirmation, alternative testing methodologies, and lab certification from SAMHSA, Texas DPS, or CAP. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 exploring direct-to-manufacturer prescription programs and vendor capabilities for state pharmacy benefit programs, though this opportunity focuses on distribution strategy rather than chemical supply. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, for generic pharmaceuticals and OTC products across multiple state and local facilities, with proposals due March 26, 2026, requiring vendors to certify cGMP compliance and Drug Supply Chain Security Act adherence. Activity under this code concentrates in Texas and Minnesota, with MMCAP's multi-state cooperative structure extending reach across Oregon and other participating jurisdictions; the code shows modest but recurring demand from corrections, public health, and cooperative purchasing entities rather than broad-based state and local procurement.